These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 19317099)

  • 1. [A fixed dose anti-HIV combination for the poor? Triomune].
    Garcia MV; Mukeba-Tshialala D; Vaira D; Moutschen M
    Rev Med Liege; 2009 Jan; 64(1):32-6. PubMed ID: 19317099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical safety of a generic fixed-dose combination of stavudine/lamivudine/névirapine (Triomune). Study of 297 cases in Togo].
    Mouhari-Touré A; Saka B; Kombat K; Tchangaï-Walla K; Pitche P
    Bull Soc Pathol Exot; 2008 Dec; 101(5):404-6. PubMed ID: 19192611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine.
    Laurent C; Kouanfack C; Koulla-Shiro S; Njoume M; Nkene YM; Ciaffi L; Brulet C; Peytavin G; Vergne L; Calmy A; Mpoudi-Ngolé E; Delaporte E
    AIDS; 2007 Mar; 21(6):768-71. PubMed ID: 17413701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenofovir resistance among HIV-infected patients failing a fixed-dose combination of stavudine, lamivudine, and nevirapine in a resource-limited setting.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Chantratitra W
    AIDS Patient Care STDS; 2007 Oct; 21(10):711-4. PubMed ID: 17949267
    [No Abstract]   [Full Text] [Related]  

  • 5. Developing countries need better antiretroviral drugs.
    Mykén N; Sundbeck B; Mpumilwa G; Andersson R
    J Int Assoc Physicians AIDS Care (Chic); 2009; 8(1):23-4. PubMed ID: 19171914
    [No Abstract]   [Full Text] [Related]  

  • 6. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial.
    Laurent C; Kouanfack C; Koulla-Shiro S; Nkoué N; Bourgeois A; Calmy A; Lactuock B; Nzeusseu V; Mougnutou R; Peytavin G; Liégeois F; Nerrienet E; Tardy M; Peeters M; Andrieux-Meyer I; Zekeng L; Kazatchkine M; Mpoudi-Ngolé E; Delaporte E
    Lancet; 2004 Jul 3-9; 364(9428):29-34. PubMed ID: 15234853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi.
    van Oosterhout JJ; Bodasing N; Kumwenda JJ; Nyirenda C; Mallewa J; Cleary PR; de Baar MP; Schuurman R; Burger DM; Zijlstra EE
    Trop Med Int Health; 2005 May; 10(5):464-70. PubMed ID: 15860093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reflections: neurology and the humanities: reflections for October.
    Birbeck GL
    Neurology; 2009 Oct; 73(15):1245-6. PubMed ID: 19822877
    [No Abstract]   [Full Text] [Related]  

  • 9. Severe ototoxicity in a health care worker who received postexposure prophylaxis with stavudine, lamivudine, and nevirapine after occupational exposure to HIV.
    Rey D; L'Héritier A; Lang JM
    Clin Infect Dis; 2002 Feb; 34(3):418-9. PubMed ID: 11774091
    [No Abstract]   [Full Text] [Related]  

  • 10. Steady-state nevirapine, lamivudine and stavudine levels in Malawian HIV-infected children on antiretroviral therapy using split Triomune 30 tablets.
    Poerksen G; Pollock L; Moons P; Chesshyre E; Burger D; Khoo S; Molyneux E
    Antivir Ther; 2010; 15(3):343-50. PubMed ID: 20516554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy of nevirapine, stavudine and lamivudine in a real-world setting.
    Shalit P; Farrell P; Lindgren P
    AIDS; 2001 Apr; 15(6):804-5. PubMed ID: 11371699
    [No Abstract]   [Full Text] [Related]  

  • 12. The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naïve adult HIV patients.
    Tin EE; Bowonwatanuwong C; Desakorn V; Wilairatana P; Krudsood S; Pitisuttithum P
    Southeast Asian J Trop Med Public Health; 2005 Mar; 36(2):362-9. PubMed ID: 15916042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective study evaluating clinical outcomes and costs of three NNRTI-based HAART regimens in Kerala, India.
    George C; Yesoda A; Jayakumar B; Lal L
    J Clin Pharm Ther; 2009 Feb; 34(1):33-40. PubMed ID: 19125901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort.
    Calmy A; Pinoges L; Szumilin E; Zachariah R; Ford N; Ferradini L;
    AIDS; 2006 May; 20(8):1163-9. PubMed ID: 16691068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: a randomized controlled trial.
    Mulenga V; Cook A; Walker AS; Kabamba D; Chijoka C; Ferrier A; Kalengo C; Kityo C; Kankasa C; Burger D; Thomason M; Chintu C; Gibb DM
    Clin Infect Dis; 2010 Nov; 51(9):1081-9. PubMed ID: 20868279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fixed dose combination of lamivudine, stavudine and nevirapine in the treatment of pediatric HIV infection: a preliminary report.
    Pensi T
    Indian Pediatr; 2007 Jul; 44(7):519-21. PubMed ID: 17684304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline CD4 cell counts and outcomes among adult treatment naive HIV patients after taking fixed dose combination GPO-VIR-S and GPO-VIR-Z in Thailand.
    Kyaw NL; Thanachartwet V; Kiertiburanakul S; Desakorn V; Chamnanchanunt S; Chierakul W; Manosuthi W; Pitisuttithum P; Sungkanuparph S
    Southeast Asian J Trop Med Public Health; 2013 Mar; 44(2):232-43. PubMed ID: 23691633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians.
    van Oosterhout JJ; Kumwenda JJ; Beadsworth M; Mateyu G; Longwe T; Burger DM; Zijlstra EE
    Antivir Ther; 2007; 12(4):515-21. PubMed ID: 17668560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Saekang N; Pairoj W; Chantratita W
    J Clin Virol; 2008 Apr; 41(4):310-3. PubMed ID: 18316243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.